Drug intelligence / Profile preview

YH0618 granule

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

YH0618 granule is a Traditional Chinese Medicine (TCM) formulation developed by the Guangdong Provincial Hospital of Chinese Medicine. It is primarily investigated for the prevention and mitigation of chemotherapy-induced alopecia (CIA) in patients with breast cancer. The drug is typically administered to patients receiving first-line taxane- or anthracycline-containing chemotherapy regimens. As a botanical-based therapy, it is designed to address hair loss through TCM principles, and clinical studies have also evaluated its impact on renal function using both Chinese and Western medical criteria.

Beyond the preview

Go deeper on YH0618 granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH0618 granule.

Explore the full profile